Clinical applications of MS-based protein quantification

Proteomics - Clinical Applications

Volumn 10, Issue 4, 2016, Pages 323-345

  Sabbagh, Bassel ^a   Mindt, Sonani ^a   Neumaier, Michael ^a   Findeisen, Peter ^a,b,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MVZ Labor Dr Limbach und Kollegen   (Germany)

^c Working Group Proteomics of the German United Society   (Germany)

Author keywords

Mass spectrometry; Protein quantification

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; GHRELIN; INSULIN; PARATHYROID HORMONE; PLASMA PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROGASTRIN RELEASING PEPTIDE; PROSTATE SPECIFIC ANTIGEN; TAU PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFERRIN; TUMOR MARKER; IMMUNOSUPPRESSIVE AGENT; PEPTIDE HORMONE; VITAMIN D;

ANALYTICAL ERROR; DATA ANALYSIS SOFTWARE; DIAGNOSTIC PROCEDURE; FEASIBILITY STUDY; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING ASSAY; MULTIPLEX ASSAY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN ENRICHMENT; PROTEOMICS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; SELECTED REACTION MONITORING ASSAY; BLOOD; DEVICES; DRUG MONITORING; MEDICAL TECHNOLOGY; NEWBORN; NEWBORN SCREENING; PROCEDURES;

BIOMARKERS, TUMOR; BLOOD PROTEINS; CHROMATOGRAPHY, LIQUID; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; MASS SPECTROMETRY; MEDICAL LABORATORY SCIENCE; NEONATAL SCREENING; PEPTIDE HORMONES; PROTEOMICS; QUALITY CONTROL; VITAMIN D;

EID: 84960384497     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201500116     Document Type: Review

References (251)

1. Yalow, R. S., Berson, S. A., Assay of plasma insulin in human subjects by immunological methods. Nature 1959, 184 (Suppl 21), 1648-1649.
2. Wu, A. H., A selected history and future of immunoassay development and applications in clinical chemistry. Clin. Chim. Acta 2006, 369, 119-124.
3. Klee, G. G., Interferences in hormone immunoassays. Clin. Lab. Med. 2004, 24, 1-18.
4. Hoofnagle, A. N., Wener, M. H., The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J. Immunol. Methods 2009, 347, 3-11.
5. Wolthuis, A., Impact of disease on interferences in blood bioanalysis. Bioanalysis 2011, 3, 2223-2231.
6. Juncker, D., Bergeron, S., Laforte, V., Li, H., Cross-reactivity in antibody microarrays and multiplexed sandwich assays: shedding light on the dark side of multiplexing. Curr. Opin. Chem. Biol. 2014, 18, 29-37.
7. Anderson, N. L., The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 2010, 56, 177-185.
8. Djoba Siawaya, J. F., Roberts, T., Babb, C., Black, G., et al., An evaluation of commercial fluorescent bead-based luminex cytokine assays. PLoS One 2008, 3, e2535.
9. McArdle, A., Butt, A. Q., Szentpetery, A., de Jager, W., et al., Developing Clinically Relevant Biomarkers in Inflammatory Arthritis: A Multi-Platform Approach for Serum Candidate Protein Discovery. Proteomics Clin. Appl. 2015. doi:10.1002/prca.201500046.
10. Nedelkov, D., Phillips, D. A., Tubbs, K. A., Nelson, R. W., Investigation of human protein variants and their frequency in the general population. Mol. Cell. Proteomics 2007, 6, 1183-1187.
11. Naldi, M., Giannone, F. A., Baldassarre, M., Domenicali, M., et al., A fast and validated mass spectrometry method for the evaluation of human serum albumin structural modifications in the clinical field. Eur. J. Mass Spectrom. 2013, 19, 491-496.
12. Vogeser, M., Seger, C., LC-MS/MS in clinical chemistry. B Analyt. Technol. Biomed. Life Sci. 2012, 883-884, 1-2.
13. Anderson, L., Hunter, C. L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 2006, 5, 573-588.
14. Krastins, B., Prakash, A., Sarracino, D. A., Nedelkov, D., et al., Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin. Biochem. 2013, 46, 399-410.
15. Fu, Q., Schoenhoff, F. S., Savage, W. J., Zhang, P., Van Eyk, J. E., Multiplex assays for biomarker research and clinical application: translational science coming of age. Proteomics Clin. Appl. 2010, 4, 271-284.
16. Boja, E. S., Rodriguez, H., Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. Proteomics 2012, 12, 1093-1110.
17. Nedelkov, D., Mass spectrometry-based protein assays for in vitro diagnostic testing. Expert Rev. Mol. Diagn. 2012, 12, 235-239.
18. Rauh, M., LC-MS/MS for protein and peptide quantification in clinical chemistry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2012, 883-884, 59-67.
19. Shi, T., Su, D., Liu, T., Tang, K., et al., Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics. Proteomics 2012, 12, 1074-1092.
20. Shi, T., Sun, X., Gao, Y., Fillmore, T. L., et al., Targeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletion. J. Proteome Res. 2013, 12, 3353-3361.
21. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J., et al., Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 2009, 27, 633-641.
22. Hoofnagle, A. N., Becker, J. O., Oda, M. N., Cavigiolio, G., et al., Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin. Chem. 2012, 58, 777-781.
23. Abbatiello, S. E., Schilling, B., Mani, D. R., Zimmerman, L. J., et al., Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma. Mol. Cell. Proteomics 2015, 14, 2357-2374.
24. Prakash, A., Rezai, T., Krastins, B., Sarracino, D., et al., Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. J. Proteome Res. 2010, 9, 6678-6688.
25. Prakash, A., Rezai, T., Krastins, B., Sarracino, D., et al., Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. J. Proteome Res. 2012, 11, 3986-3995.
26. Findeisen, P., Sismanidis, D., Riedl, M., Costina, V., Neumaier, M., Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 2005, 51, 2409-2411.
27. Thumfart, J. O., Abidi, N., Mindt, S., Costina, V., et al., LC/MS Based Monitoring of Endogenous Decay Markers for Quality Assessment of Serum Specimens. J. Proteomics Bioinform. 2015, 8, 91-97.
28. Yi, J., Warunek, D., Craft, D., Degradation and Stabilization of Peptide Hormones in Human Blood Specimens. PLoS One 2015, 10, e0134427.
29. Guder, W. G., Use of anticoagulants in diagnostic laboratory investigations and Stability of blood, plasma and serum samples. WHO/DIL/LAB/99.1 Rev.2 2002, 1-62.
30. Hassis, M. E., Niles, R. K., Braten, M. N., Albertolle, M. E., et al., Evaluating the effects of preanalytical variables on the stability of the human plasma proteome. Anal. Biochem. 2015, 478, 14-22.
31. Yi, J., Kim, C., Gelfand, C. A., Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J. Proteome Res. 2007, 6, 1768-1781.
32. Yi, J., Liu, Z., Craft, D., O'Mullan, P., et al., Intrinsic peptidase activity causes a sequential multi-step reaction (SMSR) in digestion of human plasma peptides. J. Proteome Res. 2008, 7, 5112-5118.
33. Baumann, S., Ceglarek, U., Fiedler, G. M., Lembcke, J., et al., Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 2005, 51, 973-980.
34. Rai, A. J., Gelfand, C. A., Haywood, B. C., Warunek, D. J., et al., HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005, 5, 3262-3277.
35. Karsan, A., Eigl, B., Flibotte, S., Gelmon, K., et al., Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin. Chem. 2005, 51, 1525-1528.
36. Randall, S. A., McKay, M. J., Baker, M. S., Molloy, M. P., Evaluation of blood collection tubes using selected reaction monitoring MS: implications for proteomic biomarker studies. Proteomics 2010, 10, 2050-2056.
37. Perez, V., Juega-Marino, J., Bonjoch, A., Negredo, E., et al., Evaluation of protease inhibitors containing tubes for MS-based plasma peptide profiling studies. J. Clin. Lab. Anal. 2014, 28, 364-367.
38. Skold, K., Alm, H., Scholz, B., The impact of biosampling procedures on molecular data interpretation. Mol. Cell. Proteomics 2013, 12, 1489-1501.
39. Boschetti, E., Chung, M. C., Righetti, P. G., "The quest for biomarkers": are we on the right technical track? Proteomics Clin. Appl. 2012, 6, 22-41.
40. Keshishian, H., Addona, T., Burgess, M., Kuhn, E., Carr, S. A., Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 2007, 6, 2212-2229.
41. Callesen, A. K., Madsen, J. S., Vach, W., Kruse, T. A., et al., Serum protein profiling by solid phase extraction and mass spectrometry: a future diagnostics tool? Proteomics 2009, 9, 1428-1441.
42. Yoshida, Y., Waga, I., Horii, K., Quantitative and sensitive protein detection strategies based on aptamers. Proteomics Clin. Appl. 2012, 6, 574-580.
43. Sennels, L., Salek, M., Lomas, L., Boschetti, E., et al., Proteomic analysis of human blood serum using peptide library beads. J. Proteome Res. 2007, 6, 4055-4062.
44. Longo, C., Gambara, G., Espina, V., Luchini, A., et al., A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. Exp. Dermatol. 2011, 20, 29-34.
45. Kalra, H., Adda, C. G., Liem, M., Ang, C. S., et al., Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics 2013, 13, 3354-3364.
46. Stahl-Zeng, J., Lange, V., Ossola, R., Eckhardt, K., et al., High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell. Proteomics 2007, 6, 1809-1817.
47. Thomas, A., Schanzer, W., Delahaut, P., Thevis, M., Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls. Methods 2012, 56, 230-235.
48. Ackermann, B. L., Berna, M. J., Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev. Proteomics 2007, 4, 175-186.
49. Thornalley, P. J., Rabbani, N., Detection of oxidized and glycated proteins in clinical samples using mass spectrometry-a user's perspective. Biochim. Biophys. Acta 2014, 1840, 818-829.
50. Shi, T., Fillmore, T. L., Sun, X., Zhao, R., et al., Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc. Natl. Acad. Sci. USA 2012, 109, 15395-15400.
51. Dittrich, J., Becker, S., Hecht, M., Ceglarek, U., Sample preparation strategies for targeted proteomics via proteotypic peptides in human blood using liquid chromatography tandem mass spectrometry. Proteomics Clin. Appl. 2015, 9, 5-16.
52. Lowenthal, M. S., Markey, S. P., Dosemeci, A., Quantitative mass spectrometry measurements reveal stoichiometry of principal postsynaptic density proteins. J. Proteome Res. 2015, 14, 2528-2538.
53. Qin, W., Song, Z., Fan, C., Zhang, W., et al., Trypsin immobilization on hairy polymer chains hybrid magnetic nanoparticles for ultra fast, highly efficient proteome digestion, facile 18O labeling and absolute protein quantification. Anal. Chem. 2012, 84, 3138-3144.
54. Razavi, M., Frick, L. E., LaMarr, W. A., Pope, M. E., et al., High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J. Proteome Res. 2012, 11, 5642-5649.
55. Pontillo, C., Filip, S., Borras, D. M., Mullen, W., et al., CE-MS-based proteomics in biomarker discovery and clinical application. Proteomics Clin. Appl. 2015, 9, 322-334.
56. Jankowski, J., Schanstra, J. P., Mischak, H., Body fluid peptide and protein signatures in diabetic kidney diseases. Nephrol. Dial. Transplant. 2015, 30 (Suppl 4), iv43-iv53.
57. Jantos-Siwy, J., Schiffer, E., Brand, K., Schumann, G., et al., Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J. Proteome Res. 2009, 8, 268-281.
58. Ng, E. W., Wong, M. Y., Poon, T. C., Advances in MALDI mass spectrometry in clinical diagnostic applications. Top. Curr. Chem. 2014, 336, 139-175.
59. Lin, S., Shaler, T. A., Becker, C. H., Quantification of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in a single-quadrupole ion trap. Anal. Chem. 2006, 78, 5762-5767.
60. Peterson, A. C., Russell, J. D., Bailey, D. J., Westphall, M. S., Coon, J. J., Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol. Cell. Proteomics 2012, 11, 1475-1488.
61. Domon, B., Gallien, S., Recent advances in targeted proteomics for clinical applications. Proteomics Clin. Appl. 2015, 9, 423-431.
62. Pan, S., Aebersold, R., Chen, R., Rush, J., et al., Mass spectrometry based targeted protein quantification: methods and applications. J. Proteome Res. 2009, 8, 787-797.
63. Burgess, M. W., Keshishian, H., Mani, D. R., Gillette, M. A., Carr, S. A., Simplified and efficient quantification of low-abundance proteins at very high multiplex via targeted mass spectrometry. Mol. Cell. Proteomics 2014, 13, 1137-1149.
64. Gallien, S., Duriez, E., Domon, B., Selected reaction monitoring applied to proteomics. J. Mass Spectrom. 2011, 46, 298-312.
65. Stergachis, A. B., MacLean, B., Lee, K., Stamatoyannopoulos, J. A., MacCoss, M. J., Rapid empirical discovery of optimal peptides for targeted proteomics. Nat. Methods 2011, 8, 1041-1043.
66. Abbatiello, S. E., Mani, D. R., Keshishian, H., Carr, S. A., Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry. Clin. Chem. 2010, 56, 291-305.
67. Gallien, S., Duriez, E., Demeure, K., Domon, B., Selectivity of LC-MS/MS analysis: implication for proteomics experiments. J. Proteomics 2013, 81, 148-158.
68. Picotti, P., Lam, H., Campbell, D., Deutsch, E. W., et al., A database of mass spectrometric assays for the yeast proteome. Nat. Methods 2008, 5, 913-914.
69. Deutsch, E. W., Lam, H., Aebersold, R., PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows. EMBO Rep. 2008, 9, 429-434.
70. Jones, P., Cote, R. G., Martens, L., Quinn, A. F., et al., PRIDE: a public repository of protein and peptide identifications for the proteomics community. Nucleic Acids Res. 2006, 34, D659-663.
71. Craig, R., Cortens, J. P., Beavis, R. C., Open source system for analyzing, validating, and storing protein identification data. J. Proteome Res. 2004, 3, 1234-1242.
72. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., et al., Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26, 966-968.
73. Sharma, V., Eckels, J., Taylor, G. K., Shulman, N. J., et al., Panorama: a targeted proteomics knowledge base. J. Proteome Res. 2014, 13, 4205-4210.
74. Reiter, L., Rinner, O., Picotti, P., Huttenhain, R., et al., mProphet: automated data processing and statistical validation for large-scale SRM experiments. Nat. Methods 2011, 8, 430-435.
75. Sherwood, C. A., Eastham, A., Lee, L. W., Peterson, A., et al., MaRiMba: a software application for spectral library-based MRM transition list assembly. J. Proteome Res. 2009, 8, 4396-4405.
76. Cham, J. A., Bianco, L., Barton, C., Bessant, C., MRMaid-DB: a repository of published SRM transitions. J. Proteome Res. 2010, 9, 620-625.
77. Worboys, J. D., Sinclair, J., Yuan, Y., Jorgensen, C., Systematic evaluation of quantotypic peptides for targeted analysis of the human kinome. Nat. Methods 2014, 11, 1041-1044.
78. Liu, X., Jin, Z., O'Brien, R., Bathon, J., et al., Constrained selected reaction monitoring: quantification of selected post-translational modifications and protein isoforms. Methods 2013, 61, 304-312.
79. Mani, D. R., Abbatiello, S. E., Carr, S. A., Statistical characterization of multiple-reaction monitoring mass spectrometry (MRM-MS) assays for quantitative proteomics. BMC Bioinformatics 2012, 13 Suppl 16, S9.
80. Choi, M., Chang, C. Y., Clough, T., Broudy, D., et al., MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. Bioinformatics 2014, 30, 2524-2526.
81. Turtoi, A., Mazzucchelli, G. D., De Pauw, E., Isotope coded protein label quantification of serum proteins-comparison with the label-free LC-MS and validation using the MRM approach. Talanta 2010, 80, 1487-1495.
82. Zhi, W., Wang, M., She, J. X., Selected reaction monitoring (SRM) mass spectrometry without isotope labeling can be used for rapid protein quantification. Rapid Commun. Mass Spectrom. 2011, 25, 1583-1588.
83. Negishi, A., Ono, M., Handa, Y., Kato, H., et al., Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry. Cancer Sci. 2009, 100, 514-519.
84. Cox, J., Hein, M. Y., Luber, C. A., Paron, I., et al., Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics 2014, 13, 2513-2526.
85. Sturm, M., Bertsch, A., Gropl, C., Hildebrandt, A., et al., OpenMS - an open-source software framework for mass spectrometry. BMC Bioinformatics 2008, 9, 163.
86. Park, S. K., Aslanian, A., McClatchy, D. B., Han, X., et al., Census 2: isobaric labeling data analysis. Bioinformatics 2014, 30, 2208-2209.
87. Mueller, L. N., Rinner, O., Schmidt, A., Letarte, S., et al., SuperHirn - a novel tool for high resolution LC-MS-based peptide/protein profiling. Proteomics 2007, 7, 3470-3480.
88. Zhang, R., Barton, A., Brittenden, J., Huang, J., Crowther, D., Evaluation for Computational Platforms of LC-MS Based Label-Free Quantitative Proteomics: A Global View. J. Proteomics Bioinform. 2010, 3, 260-265.
89. Pritchard, C., Quaglia, M., Ashcroft, A. E., O'Connor, G., Considering the advantages and pitfalls of the use of isotopically labeled protein standards for accurate protein quantification. Bioanalysis 2011, 3, 2797-2802.
90. Villanueva, J., Carrascal, M., Abian, J., Isotope dilution mass spectrometry for absolute quantification in proteomics: concepts and strategies. J. Proteomics 2014, 96, 184-199.
91. Kirkpatrick, D. S., Gerber, S. A., Gygi, S. P., The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 2005, 35, 265-273.
92. Kettenbach, A. N., Rush, J., Gerber, S. A., Absolute quantification of protein and post-translational modification abundance with stable isotope-labeled synthetic peptides. Nat. Protoc. 2011, 6, 175-186.
93. Beynon, R. J., Doherty, M. K., Pratt, J. M., Gaskell, S. J., Multiplexed absolute quantification in proteomics using artificial QCAT proteins of concatenated signature peptides. Nat. Methods 2005, 2, 587-589.
94. Huillet, C., Adrait, A., Lebert, D., Picard, G., et al., Accurate quantification of cardiovascular biomarkers in serum using Protein Standard Absolute Quantification (PSAQ) and selected reaction monitoring. Mol. Cell. Proteomics 2012, 11, M111.008235.
95. Zhao, Y., Jia, W., Sun, W., Jin, W., et al., Combination of improved (18)O incorporation and multiple reaction monitoring: a universal strategy for absolute quantitative verification of serum candidate biomarkers of liver cancer. J. Proteome Res. 2010, 9, 3319-3327.
96. Li, X. J., Lee, L. W., Hayward, C., Brusniak, M. Y., et al., An integrated quantification method to increase the precision, robustness, and resolution of protein measurement in human plasma samples. Clin. Proteomics 2015, 12, 3.
97. Anderson, N. L., Razavi, M., Pearson, T. W., Kruppa, G., et al., Precision of heavy-light peptide ratios measured by maldi-tof mass spectrometry. J. Proteome Res. 2012, 11, 1868-1878.
98. Annesley, T. M., Ion suppression in mass spectrometry. Clin. Chem. 2003, 49, 1041-1044.
99. Reid, J. D., Holmes, D. T., Mason, D. R., Shah, B., Borchers, C. H., Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension. J. Am. Soc. Mass Spectrom. 2010, 21, 1680-1686.
100. Camenzind, A. G., van der Gugten, J. G., Popp, R., Holmes, D. T., Borchers, C. H., Development and evaluation of an immuno-MALDI (iMALDI) assay for angiotensin I and the diagnosis of secondary hypertension. Clin. Proteomics 2013, 10, 20.
101. Popp, R., Malmstrom, D., Chambers, A. G., Lin, D., et al., An automated assay for the clinical measurement of plasma renin activity by immuno-MALDI (iMALDI). Biochim. Biophys. Acta 2015, 1854, 547-558.
102. Nilse, L., Sigloch, F. C., Biniossek, M. L., Schilling, O., Toward improved peptide feature detection in quantitative proteomics using stable isotope labeling. Proteomics Clin. Appl. 2015, 9, 706-714.
103. Brusniak, M. Y., Chu, C. S., Kusebauch, U., Sartain, M. J., et al., An assessment of current bioinformatic solutions for analyzing LC-MS data acquired by selected reaction monitoring technology. Proteomics 2012, 12, 1176-1184.
104. Colangelo, C. M., Chung, L., Bruce, C., Cheung, K. H., Review of software tools for design and analysis of large scale MRM proteomic datasets. Methods 2013, 61, 287-298.
105. Lange, V., Malmstrom, J. A., Didion, J., King, N. L., et al., Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring. Mol. Cell. Proteomics 2008, 7, 1489-1500.
106. Sandin, M., Teleman, J., Malmstrom, J., Levander, F., Data processing methods and quality control strategies for label-free LC-MS protein quantification. Biochim. Biophys. Acta 2014, 1844, 29-41.
107. van den Broek, I., Romijn, F. P., Smit, N. P., van der Laarse, A., et al., Quantifying protein measurands by peptide measurements: where do errors arise? J. Proteome Res. 2015, 14, 928-942.
108. Friedman, D. B., Andacht, T. M., Bunger, M. K., Chien, A. S., et al., The ABRF Proteomics Research Group studies: educational exercises for qualitative and quantitative proteomic analyses. Proteomics 2011, 11, 1371-1381.
109. Percy, A. J., Chambers, A. G., Smith, D. S., Borchers, C. H., Standardized protocols for quality control of MRM-based plasma proteomic workflows. J. Proteome Res. 2013, 12, 222-233.
110. Kennedy, J. J., Abbatiello, S. E., Kim, K., Yan, P., et al., Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat. Methods 2014, 11, 149-155.
111. Kuhn, E., Whiteaker, J. R., Mani, D. R., Jackson, A. M., et al., Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol. Cell. Proteomics 2012, 11, M111.013854.
112. Lebert, D., Louwagie, M., Goetze, S., Picard, G., et al., DIGESTIF: a universal quality standard for the control of bottom-up proteomics experiments. J. Proteome Res. 2015, 14, 787-803.
113. Gallien, S., Bourmaud, A., Domon, B., A simple protocol to routinely assess the uniformity of proteomics analyses. J. Proteome Res. 2014, 13, 2688-2695.
114. Bereman, M. S., Johnson, R., Bollinger, J., Boss, Y., et al., Implementation of statistical process control for proteomic experiments via LC MS/MS. J. Am. Soc. Mass Spectrom. 2014, 25, 581-587.
115. Mohammed, Y., Percy, A. J., Chambers, A. G., Borchers, C. H., Qualis-SIS: automated standard curve generation and quality assessment for multiplexed targeted quantitative proteomic experiments with labeled standards. J. Proteome Res. 2015, 14, 1137-1146.
116. Kilpatrick, E. L., Bunk, D. M., Reference measurement procedure development for C-reactive protein in human serum. Anal. Chem. 2009, 81, 8610-8616.
117. Cabaleiro, D. R., Stockl, D., Kaufman, J. M., Fiers, T., Thienpont, L. M., Feasibility of standardization of serum C-peptide immunoassays with isotope-dilution liquid chromatography-tandem mass spectrometry. Clin. Chem. 2006, 52, 1193-1196.
118. Vesper, H. W., Thienpont, L. M., Traceability in laboratory medicine. Clin. Chem. 2009, 55, 1067-1075.
119. Jeppsson, J. O., Kobold, U., Barr, J., Finke, A., et al., Approved IFCC reference method for the measurement of HbA1c in human blood. Clin. Chem. Lab. Med. 2002, 40, 78-89.
120. Barr, J. R., Maggio, V. L., Patterson, D. G., Jr., Cooper, G. R., et al., Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin. Chem. 1996, 42, 1676-1682.
121. Yu, Y., Xu, J., Liu, Y., Chen, Y., Quantification of human serum transferrin using liquid chromatography-tandem mass spectrometry based targeted proteomics. B Analyt. Technol. Biomed. Life Sci. 2012, 902, 10-15.
122. Chen, Z., Caulfield, M. P., McPhaul, M. J., Reitz, R. E., et al., Quantitative insulin analysis using liquid chromatography-tandem mass spectrometry in a high-throughput clinical laboratory. Clin. Chem. 2013, 59, 1349-1356.
123. Armbruster, D., Miller, R. R., The Joint Committee for Traceability in Laboratory Medicine (JCTLM): a global approach to promote the standardisation of clinical laboratory test results. Clin. Biochem. Rev. 2007, 28, 105-113.
124. Kessler, A., Siekmann, L., Weykamp, C., Geilenkeuser, W. J., et al., External Quality Assessment Scheme for reference laboratories - review of 8 years' experience. Clin. Chem. Lab. Med. 2013, 51, 997-1005.
125. Martinez-Morillo, E., Nielsen, H. M., Batruch, I., Drabovich, A. P., et al., Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. J. Proteome Res. 2014, 13, 1077-1087.
126. Lassman, M. E., McLaughlin, T. M., Zhou, H., Pan, Y., et al., Simultaneous quantitation and size characterization of apolipoprotein(a) by ultra-performance liquid chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 2014, 28, 1101-1106.
127. McConnell, J. P., Guadagno, P. A., Dayspring, T. D., Hoefner, D. M., et al., Lipoprotein(a) mass: a massively misunderstood metric. J. Clin. Lipidol. 2014, 8, 550-553.
128. Chang, C. T., Yang, C. Y., Tsai, F. J., Lin, S. Y., Chen, C. J., Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease. Biomed. Res. Int. 2015, 2015, 164846.
129. Zimmerman, T. A., Wang, M., Lowenthal, M. S., Turko, I. V., Phinney, K. W., Quantification of transferrin in human serum using both QconCAT and synthetic internal standards. Anal. Chem. 2013, 85, 10362-10368.
130. deWilde, A., Sadilkova, K., Sadilek, M., Vasta, V., Hahn, S. H., Tryptic peptide analysis of ceruloplasmin in dried blood spots using liquid chromatography-tandem mass spectrometry: application to newborn screening. Clin. Chem. 2008, 54, 1961-1968.
131. Hoofnagle, A. N., Becker, J. O., Wener, M. H., Heinecke, J. W., Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin. Chem. 2008, 54, 1796-1804.
132. Kushnir, M. M., Rockwood, A. L., Roberts, W. L., Abraham, D., et al., Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. Clin. Chem. 2013, 59, 982-990.
133. Netzel, B. C., Grebe, S. K., Carranza Leon, B. G., Castro, M. R., et al., Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes. J. Clin. Endocrinol. Metab. 2015, 100, E1074-1083.
134. Chen, Y., Snyder, M. R., Zhu, Y., Tostrud, L. J., et al., Simultaneous phenotyping and quantification of alpha-1-antitrypsin by liquid chromatography-tandem mass spectrometry. Clin. Chem. 2011, 57, 1161-1168.
135. Rosenzweig, C. N., Zhang, Z., Sun, X., Sokoll, L. J., et al., Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J. Urol. 2009, 181, 1407-1414.
136. Razavi, M., Johnson, L. D., Lum, J. J., Kruppa, G., et al., Quantification of a proteotypic peptide from protein C inhibitor by liquid chromatography-free SISCAPA-MALDI mass spectrometry: application to identification of recurrence of prostate cancer. Clin. Chem. 2013, 59, 1514-1522.
137. Bergen, H. R., 3rd, Zeldenrust, S. R., Naylor, S., An on-line assay for clinical detection of amyloidogenic transthyretin variants directly from serum. Amyloid 2003, 10, 190-197.
138. O'Brien, J. F., Bergen, H. R., 3rd, Transthyretin mass determination for detection of transthyretin familial amyloid. Methods Mol. Biol. 2009, 492, 353-365.
139. Daniel, Y. A., Turner, C., Haynes, R. M., Hunt, B. J., Dalton, R. N., Rapid and specific detection of clinically significant haemoglobinopathies using electrospray mass spectrometry-mass spectrometry. Br. J. Haematol. 2005, 130, 635-643.
140. Rauh, M., Groschl, M., Rascher, W., Simultaneous quantification of ghrelin and desacyl-ghrelin by liquid chromatography-tandem mass spectrometry in plasma, serum, and cell supernatants. Clin. Chem. 2007, 53, 902-910.
141. Kumar, V., Barnidge, D. R., Chen, L. S., Twentyman, J. M., et al., Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin. Chem. 2010, 56, 306-313.
142. Lopez, M. F., Rezai, T., Sarracino, D. A., Prakash, A., et al., Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin. Chem. 2010, 56, 281-290.
143. Sturgeon, C. M., Sprague, S. M., Metcalfe, W., Variation in parathyroid hormone immunoassay results-a critical governance issue in the management of chronic kidney disease. Nephrol. Dial. Transplant. 2011, 26, 3440-3445.
144. Owen, W. E., Roberts, W. L., Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin. Chem. 2004, 50, 257-259.
145. Rodriguez-Cabaleiro, D., Van Uytfanghe, K., Stove, V., Fiers, T., Thienpont, L. M., Pilot study for the standardization of insulin immunoassays with isotope dilution liquid chromatography/tandem mass spectrometry. Clin. Chem. 2007, 53, 1462-1469.
146. Thevis, M., Thomas, A., Schanzer, W., Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom. Rev. 2008, 27, 35-50.
147. Oran, P. E., Jarvis, J. W., Borges, C. R., Sherma, N. D., Nelson, R. W., Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. Proteomics Clin. Appl. 2011, 5, 454-459.
148. Hess, C., Thomas, A., Thevis, M., Stratmann, B., et al., Simultaneous determination and validated quantification of human insulin and its synthetic analogues in human blood serum by immunoaffinity purification and liquid chromatography-mass spectrometry. Anal. Bioanal. Chem. 2012, 404, 1813-1822.
149. Peterman, S., Niederkofler, E. E., Phillips, D. A., Krastins, B., et al., An automated, high-throughput method for targeted quantification of intact insulin and its therapeutic analogs in human serum or plasma coupling mass spectrometric immunoassay with high resolution and accurate mass detection (MSIA-HR/AM). Proteomics 2014, 14, 1445-1456.
150. Xuereb, F., Chaignepain, S., Breilh, D., Godde, F., et al., Quantitative analysis of erythropoietin in human plasma by tandem mass spectrometry. Anal. Bioanal. Chem. 2011, 400, 2073-2084.
151. Yim, J. H., Yoon, I., Yang, H. J., Kim, S. K., et al., Quantification of recombinant human erythropoietin by amino acid analysis using isotope dilution liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 2014, 406, 4401-4409.
152. Chaabo, A., de Ceaurriz, J., Buisson, C., Tabet, J. C., Lasne, F., Simultaneous quantification and qualification of synacthen in plasma. Anal. Bioanal. Chem. 2011, 399, 1835-1843.
153. Arsene, C. G., Henrion, A., Diekmann, N., Manolopoulou, J., Bidlingmaier, M., Quantification of growth hormone in serum by isotope dilution mass spectrometry. Anal. Biochem. 2010, 401, 228-235.
154. Wu, S. L., Amato, H., Biringer, R., Choudhary, G., et al., Targeted proteomics of low-level proteins in human plasma by LC/MSn: using human growth hormone as a model system. J. Proteome Res. 2002, 1, 459-465.
155. Kirsch, S., Widart, J., Louette, J., Focant, J. F., De Pauw, E., Development of an absolute quantification method targeting growth hormone biomarkers using liquid chromatography coupled to isotope dilution mass spectrometry. J. Chromatogr. A 2007, 1153, 300-306.
156. Sturgeon, C. M., Hoffman, B. R., Chan, D. W., Ch'ng, S. L., et al., National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin. Chem. 2008, 54, e1-e10.
157. Fortin, T., Salvador, A., Charrier, J. P., Lenz, C., et al., Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol. Cell. Proteomics 2009, 8, 1006-1015.
158. Liu, T., Hossain, M., Schepmoes, A. A., Fillmore, T. L., et al., Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. J. Proteomics 2012, 75, 4747-4757.
159. Vermassen, T., Speeckaert, M. M., Lumen, N., Rottey, S., Delanghe, J. R., Glycosylation of prostate specific antigen and its potential diagnostic applications. Clin. Chim. Acta 2012, 413, 1500-1505.
160. Li, Y., Sokoll, L. J., Rush, J., Meany, D., et al., Targeted detection of prostate cancer proteins in serum using heavy-isotope-labeled-peptide standards and MALDI-TOF/TOF. Proteomics Clin. Appl. 2009, 3, 597-608.
161. Carter, H. B., Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J. Androl. 2012, 14, 355-360.
162. Chen, Y. T., Tuan, L. P., Chen, H. W., Wei, I. A., et al., Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry. Anal. Chem. 2015, 87, 545-553.
163. Ahn, Y. H., Lee, J. Y., Lee, J. Y., Kim, Y. S., et al., Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J. Proteome Res. 2009, 8, 4216-4224.
164. Winther, B., Moi, P., Nordlund, M. S., Lunder, N., et al., Absolute ProGRP quantification in a clinical relevant concentration range using LC-MS/MS and a comprehensive internal standard. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877, 1359-1365.
165. Winther, B., Nordlund, M., Paus, E., Reubsaet, L., Halvorsen, T. G., Immuno-capture as ultimate sample cleanup in LC-MS/MS determination of the early stage biomarker ProGRP. J. Sep. Sci. 2009, 32, 2937-2943.
166. Humpel, C., Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol. 2011, 29, 26-32.
167. Bibl, M., Gallus, M., Welge, V., Lehmann, S., et al., Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-beta peptides. Proteomics Clin. Appl. 2012, 6, 163-169.
168. Portelius, E., Gustavsson, M. K., Zetterberg, H., Andreasson, U., Blennow, K., Evaluation of the performance of novel Abeta isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient. Neurodegener. Dis. 2012, 10, 138-140.
169. Pannee, J., Gobom, J., Shaw, L. M., Korecka, M., et al., Round robin test on quantification of amyloid-beta 1-42 in cerebrospinal fluid by mass spectrometry. Alzheimers Dement. 2015, 12, Seiten 55-59.
170. Bros, P., Delatour, V., Vialaret, J., Lalere, B., et al., Quantitative detection of amyloid-beta peptides by mass spectrometry: state of the art and clinical applications. Clin. Chem. Lab. Med. 2015, 53, 1483-1493.
171. Portelius, E., Westman-Brinkmalm, A., Zetterberg, H., Blennow, K., Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome Res. 2006, 5, 1010-1016.
172. Delaby, C., Gabelle, A., Meynier, P., Loubiere, V., et al., Development and validation of dried matrix spot sampling for the quantitative determination of amyloid beta peptides in cerebrospinal fluid. Clin. Chem. Lab. Med. 2014, 52, 649-655.
173. Portelius, E., Tran, A. J., Andreasson, U., Persson, R., et al., Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J. Proteome Res. 2007, 6, 4433-4439.
174. Pannee, J., Portelius, E., Oppermann, M., Atkins, A., et al., A selected reaction monitoring (SRM)-based method for absolute quantification of Abeta38, Abeta40, and Abeta42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. J. Alzheimers Dis. 2013, 33, 1021-1032.
175. Du, C., Ramaley, C., McLean, H., Leonard, S. C., Miller, J., High-performance liquid chromatography coupled with tandem mass spectrometry for the detection of amyloid Beta peptide related with Alzheimer's disease. J. Biomol. Tech. 2005, 16, 356-363.
176. Dillen, L., Cools, W., Vereyken, L., Timmerman, P., A screening UHPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species. Bioanalysis 2011, 3, 45-55.
177. Korecka, M., Waligorska, T., Figurski, M., Toledo, J. B., et al., Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J. Alzheimers Dis. 2014, 41, 441-451.
178. Mattsson, N., Zegers, I., Andreasson, U., Bjerke, M., et al., Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid beta42. Biomark. Med. 2012, 6, 409-417.
179. Simon, R., Girod, M., Fonbonne, C., Salvador, A., et al., Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides. Mol. Cell. Proteomics 2012, 11, 1389-1403.
180. Nanjappa, V., Thomas, J. K., Marimuthu, A., Muthusamy, B., et al., Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic Acids Res. 2014, 42, D959-965.
181. Rosenberger, G., Koh, C. C., Guo, T., Rost, H. L., et al., A repository of assays to quantify 10, 000 human proteins by SWATH-MS. Sci. Data 2014, 1, 140031.
182. Mischak, H., Apweiler, R., Banks, R., Conaway, M., et al., Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin. Appl. 2007, 1, 148-156.
183. Chambers, A. G., Percy, A. J., Yang, J., Camenzind, A. G., Borchers, C. H., Multiplexed quantitation of endogenous proteins in dried blood spots by multiple reaction monitoring-mass spectrometry. Mol. Cell. Proteomics 2013, 12, 781-791.
184. Sajic, T., Liu, Y., Aebersold, R., Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications. Proteomics Clin. Appl. 2015, 9, 307-321.
185. Krisp, C., Randall, S. A., McKay, M. J., Molloy, M. P., Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies. Proteomics Clin. Appl. 2012, 6, 42-59.
186. Shen, X., Young, R., Canty, J. M., Qu, J., Quantitative proteomics in cardiovascular research: global and targeted strategies. Proteomics Clin. Appl. 2014, 8, 488-505.
187. Chaerkady, R., Pandey, A., Quantitative proteomics for identification of cancer biomarkers. Proteomics Clin. Appl. 2007, 1, 1080-1089.
188. Frantzi, M., Latosinska, A., Fluhe, L., Hupe, M. C., et al., Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat. Rev. Urol. 2015, 12, 317-330.
189. Ueda, K., Glycoproteomic strategies: From discovery to clinical application of cancer carbohydrate biomarkers. Proteomics Clin. Appl. 2013, 7, 607-617.
190. Montine, T. J., Woltjer, R. L., Pan, C., Montine, K. S., Zhang, J., Liquid chromatography with tandem mass spectrometry-based proteomic discovery in aging and Alzheimer's disease. NeuroRx 2006, 3, 336-343.
191. Filiou, M. D., Turck, C. W., Martins-de-Souza, D., Quantitative proteomics for investigating psychiatric disorders. Proteomics Clin. Appl. 2011, 5, 38-49.
192. Yepes, D., Costina, V., Pilz, L. R., Hofheinz, R., et al., Multiplex profiling of tumor associated proteolytic activity in serum of colorectal cancer patients. Proteomics Clin. Appl. 2014, 8, 208-316.
193. Villanueva, J., Nazarian, A., Lawlor, K., Yi, S. S., et al., A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery. Mol. Cell. Proteomics 2008, 7, 509-518.
194. Peccerella, T., Lukan, N., Hofheinz, R., Schadendorf, D., et al., Endoprotease profiling with double-tagged peptide substrates: a new diagnostic approach in oncology. Clin. Chem. 2010, 56, 272-280.
195. Findeisen, P., Costina, V., Yepes, D., Hofheinz, R., Neumaier, M., Functional protease profiling with reporter peptides in serum specimens of colorectal cancer patients: demonstration of its routine diagnostic applicability. J. Exp. Clin. Cancer Res. 2012, 31, 56.
196. Sabbagh, B., Costina, V., Buchheidt, D., Reinwald, M., et al., Functional protease profiling for laboratory based diagnosis of invasive aspergillosis. Int. J. Oncol. 2015, 47, 143-150.
197. Zhang, Z., Chan, D. W., The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol. Biomarkers. Prev. 2010, 19, 2995-2999.
198. Mischak, H., Ioannidis, J. P., Argiles, A., Attwood, T. K., et al., Implementation of proteomic biomarkers: making it work. Eur. J. Clin. Invest. 2012, 42, 1027-1036.
199. Di Meo, A., Diamandis, E. P., Rodriguez, H., Hoofnagle, A. N., et al., What is wrong with clinical proteomics? Clin. Chem. 2014, 60, 1258-1266.
200. Heegaard, N. H., Ostergaard, O., Bahl, J. M., Overgaard, M., et al., Important options available-from start to finish-for translating proteomics results to clinical chemistry. Proteomics Clin. Appl. 2015, 9, 235-252.
201. Roberts, N. W., Christenson, R. H., Price, C. P., Searching for evidence: a guide to finding the evidence in laboratory medicine. Ann. Clin. Biochem. 2014, 51, 326-334.
202. Ioannidis, J. P., A roadmap for successful applications of clinical proteomics. Proteomics Clin. Appl. 2011, 5, 241-247.
203. Misra, S., Barth, J. H., How good is the evidence base for test selection in clinical guidelines? Clin. Chim. Acta 2014, 432, 27-32.
204. Aakre, K. M., Langlois, M. R., Watine, J., Barth, J. H., et al., Critical review of laboratory investigations in clinical practice guidelines: proposals for the description of investigation. Clin. Chem. Lab.Med. 2013, 51, 1217-1226.
205. Lehmann, S., Hoofnagle, A., Hochstrasser, D., Brede, C., et al., Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. Clin. Chem. Lab. Med. 2013, 51, 919-935.
206. Carr, S. A., Abbatiello, S. E., Ackermann, B. L., Borchers, C., et al., Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol. Cell. Proteomics 2014, 13, 907-917.
207. Braga, F., Panteghini, M., Verification of in vitro medical diagnostics (IVD) metrological traceability: responsibilities and strategies. Clin. Chim. Acta 2014, 432, 55-61.
208. Westgard, J. O., Westgard, S. A., The quality of laboratory testing today: an assessment of sigma metrics for analytic quality using performance data from proficiency testing surveys and the CLIA criteria for acceptable performance. Am. J. Clin. Pathol. 2006, 125, 343-354.
209. Booth, B., Arnold, M. E., DeSilva, B., Amaravadi, L., et al., Workshop report: Crystal City V-quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance. AAPS J. 2015, 17, 277-288.
210. Fuzery, A. K., Levin, J., Chan, M. M., Chan, D. W., Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin. Proteomics 2013, 10, 13.
211. Howes, K., Regulatory challenges for diagnostic development - a European perspective. Expert Opin. Med. Diagn. 2007, 1, 153-157.
212. Manolis, E., Vamvakas, S., Isaac, M., New pathway for qualification of novel methodologies in the European Medicines Agency. Proteomics Clin. Appl. 2011, 5, 248-255.
213. Adaway, J. E., Keevil, B. G., Owen, L. J., Liquid chromatography tandem mass spectrometry in the clinical laboratory. Ann. Clin. Biochem. 2015, 52, 18-38.
214. Liu, Y., Buil, A., Collins, B. C., Gillet, L. C., et al., Quantitative variability of 342 plasma proteins in a human twin population. Mol. Syst. Biol. 2015, 11, 786.
215. Ignjatovic, V., Lai, C., Summerhayes, R., Mathesius, U., et al., Age-Related Differences in Plasma Proteins: How Plasma Proteins Change from Neonates to Adults. PLoS ONE 2011, 6, e17213.
216. Paulovich, A. G., Whiteaker, J. R., Hoofnagle, A. N., Wang, P., The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. Proteomics Clin. Appl. 2008, 2, 1386-1402.
217. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
218. Zhang, Y. V., Rockwood, A., Impact of automation on mass spectrometry. Clin. Chim. 2015, 450, 298-303.
219. Eckhard, U., Marino, G., Butler, G. S., Overall, C. M., Positional proteomics in the era of the human proteome project on the doorstep of precision medicine. Biochimie 2015, 122, 110-118.
220. Gonzalez-Antuna, A., Rodriguez-Gonzalez, P., Ohlendorf, R., Henrion, A., et al., Determination of Cystatin C in human serum by isotope dilution mass spectrometry using mass overlapping peptides. J. Proteomics 2015, 112, 141-155.
221. Barnidge, D. R., Dasari, S., Botz, C. M., Murray, D. H., et al., Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J. Proteome Res. 2014, 13, 1419-1427.
222. Kim, Y. J., Gallien, S., El-Khoury, V., Goswami, P., et al., Quantification of SAA1 and SAA2 in lung cancer plasma using the isotype-specific PRM assays. Proteomics 2015, 15, 3116-3125.
223. Yang, T., Xu, F., Zhao, Y., Wang, S., et al., A liquid chromatography-tandem mass spectrometry-based targeted proteomics approach for the assessment of transferrin receptor levels in breast cancer. Proteomics Clin. Appl. 2014, 8, 773-782.
224. Vila-Rico, M., Colome-Calls, N., Martin-Castel, L., Gay, M., et al., Quantitative analysis of post-translational modifications in human serum transthyretin associated with familial amyloidotic polyneuropathy by targeted LC-MS and intact protein MS. MS. J. Proteomics 2015, 127, 234-246.
225. Sinclair, J., Timms, J. F., Quantitative profiling of serum samples using TMT protein labelling, fractionation and LC-MS/MS. Methods 2011, 54, 361-369.
226. Kay, R. G., Gregory, B., Grace, P. B., Pleasance, S., The application of ultra-performance liquid chromatography/tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum. Rapid Commun. Mass Spectrom. 2007, 21, 2585-2593.
227. Mann, B., Madera, M., Klouckova, I., Mechref, Y., et al., A quantitative investigation of fucosylated serum glycoproteins with application to esophageal adenocarcinoma. Electrophoresis 2010, 31, 1833-1841.
228. Spellman, D. S., Wildsmith, K. R., Honigberg, L. A., Tuefferd, M., et al., Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. Proteomics Clin. Appl. 2015, 9, 715-731.
229. Kim, Y. J., Sertamo, K., Pierrard, M. A., Mesmin, C., et al., Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach. J. Proteome Res. 2015, 14, 1412-1419.
230. van den Broek, I., Sparidans, R. W., van Winden, A. W., Gast, M. C., et al., The absolute quantification of eight inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients. Proteomics. Clin. Appl. 2010, 4, 931-939.
231. Cantley, L. G., Colangelo, C. M., Stone, K. L., Chung, L., et al., Development of a Targeted Urine Proteome Assay for Kidney Diseases. Proteomics Clin. Appl. 2015, 10, 58-74.
232. Ansari, D., Andersson, R., Bauden, M. P., Andersson, B., et al., Protein deep sequencing applied to biobank samples from patients with pancreatic cancer. J. Cancer Res. Clin. Oncol. 2015, 141, 369-380.
233. Selevsek, N., Matondo, M., Sanchez Carbayo, M., Aebersold, R., Domon, B., Systematic quantification of peptides/proteins in urine using selected reaction monitoring. Proteomics 2011, 11, 1135-1147.
234. Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J., et al., Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics 2009, 8, 1860-1877.
235. Addona, T. A., Shi, X., Keshishian, H., Mani, D. R., et al., A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat. Biotechnol. 2011, 29, 635-643.
236. Ceglarek, U., Dittrich, J., Becker, S., Baumann, F., et al., Quantification of seven apolipoproteins in human plasma by proteotypic peptides using fast LC-MS/MS. Clin. Appl. 2013, 7, 794-801.
237. Lancrajan, I., Schneider-Stock, R., Naschberger, E., Schellerer, V. S., et al., Absolute quantification of DcR3 and GDF15 from human serum by LC-ESI MS. J. Cell. Mol. Med. 2015, 19, 1656-1671.
238. Cima, I., Schiess, R., Wild, P., Kaelin, M., et al., Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc. Natl. Acad. Sci. USA 2011, 108, 3342-3347.
239. Elschenbroich, S., Ignatchenko, V., Clarke, B., Kalloger, S. E., et al., In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. J. Proteome Res. 2011, 10, 2286-2299.
240. Whiteaker, J. R., Lin, C., Kennedy, J., Hou, L., et al., A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat. Biotechnol. 2011, 29, 625-634.
241. Radon, T. P., Massat, N. J., Jones, R., Alrawashdeh, W., et al., Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. Clin. Cancer Res. 2015, 21, 3512-3521.
242. Mills, J. R., Barnidge, D. R., Murray, D. L., Detecting monoclonal immunoglobulins in human serum using mass spectrometry. Methods 2015, 81, 56-65.
243. Choi, Y. S., Hou, S., Choe, L. H., Lee, K. H., Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2013, 930, 129-135.
244. Hu, Y., Hosseini, A., Kauwe, J. S., Gross, J., et al., Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics Clin. Appl. 2007, 1, 1373-1384.
245. Remily-Wood, E. R., Liu, R. Z., Xiang, Y., Chen, Y., et al., A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin. Appl. 2011, 5, 383-396.
246. Huttenhain, R., Soste, M., Selevsek, N., Rost, H., et al., Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci. Transl. Med. 2012, 4, 142ra194.
247. Cerciello, F., Choi, M., Nicastri, A., Bausch-Fluck, D., et al., Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring. Clin. Proteomics 2013, 10, 16.
248. Nicol, G. R., Han, M., Kim, J., Birse, C. E., et al., Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients. Mol. Cell. Proteomics 2008, 7, 1974-1982.
249. Pan, S., Chen, R., Brand, R. E., Hawley, S., et al., Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J. Proteome Res. 2012, 11, 1937-1948.
250. Keshishian, H., Addona, T., Burgess, M., Mani, D. R., et al., Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 2009, 8, 2339-2349.
251. Domanski, D., Percy, A. J., Yang, J., Chambers, A. G., et al., MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics 2012, 12, 1222-1243.